Pitting new treatments for XXXX against old ones: how do they fare?

@entity1 @entity13851 @entity11441 @entity2225 @entity786 @entity1072 @entity5805 @entity3118 @entity6490
UNASSIGNED: Significant progress has been made in the treatment of @entity1072 ( @entity1072 ) @entity1 during the last two decades. In this review we present a personal case study for discussion on contemporary management in @entity1072 . Presently immunochemotherapy using @entity3118 , @entity786 , and rituximab (FCR) is the standard upfront regimen for physically fit @entity1 requiring treatment. @entity1 older than 65  years can be treated with modified doses of FCR, @entity11441 , or @entity5805 combined with anti- @entity2225 antibody. This treatment can be repeated at relapse when the duration of response is over 2  years. @entity1 at high risk (with 17p deletion or early relapse) need alternative treatment with novel agents, e.g. @entity6490 or @entity13851 . However, the optimal use of the novel agents in terms of duration, combinations, and long-term adverse effects is unknown. In selected eligible @entity1 at high risk, allogeneic transplantation should be considered. Clinical trials in all stages of treatment are encouraged.
